Anti-Inflammatory Biologics Industry Growth Insights: Revenue Forecast to 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the anti-inflammatory biologics market from 2026–2035 with trusted insights from The Business Research Company
What was the valuation of the Anti-Inflammatory Biologics Market in 2026, and what figure is it projected to hit by 2030?
The anti-inflammatory biologics market has seen significant expansion in recent years. This market is set to expand from $118.02 billion in 2025 to $128.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. The historical development of this market can be ascribed to a limited supply of biologics, reliance on traditional anti-inflammatory drugs, increasing prevalence of rheumatoid arthritis and psoriasis, growth of hospital and clinic infrastructure, and rising investment in immunology research.
The anti-inflammatory biologics market size is anticipated to expand significantly over the coming years, projected to reach $180.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This growth during the forecast period is attributable to the advancement of next-generation cytokine inhibitors, the increased availability of home care and self-administration alternatives, a surge in regulatory approvals and accelerated clinical trial procedures, escalating investment in precision medicine and biologics research and development, and the proliferation of partnerships between pharmaceutical and biotech enterprises. Significant trends for the forecast period include the growing acceptance of targeted biologics for chronic inflammatory conditions, the broader adoption of subcutaneous and injectable drug delivery systems, an increase in clinical trials and research for innovative anti-inflammatory biologics, a heightened focus on personalized treatment strategies, and improved awareness and access to biologics in developing markets.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp
Which Drivers Are Affecting Market Participation In The Anti-Inflammatory Biologics Market?
The increasing occurrence of arthritis is anticipated to fuel the expansion of the anti-inflammatory biologics market in the foreseeable future. Arthritis is defined as the inflammation or swelling affecting one or more joints, leading to discomfort, rigidity, and restricted mobility, frequently intensifying with advancing age. This escalating prevalence of arthritis largely stems from growing obesity levels, where surplus body weight exerts extra pressure on joints, contributing to inflammation and the deterioration of joint tissue. Anti-inflammatory biologics offer benefits for arthritis patients by targeting precise elements of the immune system, thereby diminishing inflammation, decelerating joint deterioration, alleviating symptoms, and enhancing both physical capabilities and overall life quality for individuals suffering from moderate to severe forms of the condition. As an illustration, data from January 2024, provided by the Office for Health Improvement and Disparities, a UK government body, indicated that in 2023, 18.4% of individuals aged 16 and above reported experiencing a long-term MSK condition, which was an increase from 17.6% in 2022. Consequently, the increasing incidence of arthritis is a key factor propelling the expansion of the anti-inflammatory biologics market.
What Segment Categories Are Covered In The Anti-Inflammatory Biologics Market?
The anti-inflammatory biologics market covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics
Which Trends Are Shaping Activity Within The Anti-Inflammatory Biologics Market?
Leading companies in the anti-inflammatory biologics market are concentrating on creating novel solutions, such as interleukin-6 (IL-6) receptor antagonists, to address chronic inflammatory diseases with increased precision and fewer adverse effects. Interleukin-6 (IL-6) receptor antagonists are a class of biologic medicines that impede the IL-6 receptor to lessen inflammation and immune responses in conditions like rheumatoid arthritis. For example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology firm, obtained approval from the US Food and Drug Administration (FDA) for Kevzara, marking it as the initial and sole biologic treatment specifically indicated for individuals with polymyalgia rheumatica (PMR) who exhibit an inadequate response to corticosteroids. Kevzara functions as a fully human monoclonal antibody that obstructs the IL-6 receptor, thereby helping to diminish inflammation associated with PMR, a condition characterized by muscle pain and stiffness, predominantly affecting older adults. In contrast to conventional steroids, which present risks such as osteoporosis and diabetes with extended usage, Kevzara offers a more directed, steroid-sparing strategy that supports better patient results and enhanced long-term safety.
Which Key Market Players Are Investing In Expansion And Innovation Within The Anti-Inflammatory Biologics Market?
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report
Which Regions Are Poised For Strategic Growth In The Anti-Inflammatory Biologics Market?
North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Anti-Inflammatory Biologics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp
Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2026, By The Business Research Company
Anti Inflammatory Therapeutics Market Report 2026
Non Steroidal Anti Inflammatory Drugs Market Report 2026
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
